June 11 reveals critical progress across cell and gene therapies, metabolic disease drug research, and strategic industry partnerships …
June 11 reveals critical progress across cell and gene therapies, metabolic disease drug research, and strategic industry partnerships …
Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
Sanofi’s acquisition of Blueprint Medicines, Eli Lilly’s gene-editing push, and several cross-continental alliances mark a new phase in …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
Australia unveiled a major investment to advance brain cancer clinical research, spotlighting landmark immunotherapy breakthroughs and patient-focused innovation
Megafunding rounds and regulatory momentum reshaped the biotech investment landscape, signaling growing confidence in transformative clinical innovation.
Japanese pharma giant Taiho invests up to $1.14 billion in Swiss innovation, expanding its portfolio in antibody-drug conjugates …
Regeneron and Sanofi bolster their immunology-focused portfolios by acquiring global rights to a promising monoclonal antibody targeting autoimmune …
Already a subscriber? Log in